Calcium and Potassium Regulators

15 Drugs classified under this therapeutic system

Bisphosphonate. Zoledronic Acid 5 mg / 100 ml.
SOL. FOR INFUS: 1 x 100 ml.
Single I.V. infus. 5 mg x 1 yr. See lit.
Tmt. Paget’s dis. of bone. Tmt. osteoporos.
post-menopaus. women, men at incr. risk
fracture, incl. recent low trauma hip
fracture. Tmt./prevent. glucocorticoidinduc.
osteoporos. Prevent. post
menopaus. osteoporos. in women when
biphosphonate ther. indicat.
C/I: Hypersens. to excips. or any
bisphosphonates, hypocalcem., pregn.,
lact., sev. ren. impair. (CLcr<35 mL/min).

Vitamin D3 Analog. Alfacalcidol 0.25, 0.5, 1 mcg.
CAPS: 50.
Renal osteodystrophy,
hypoparathyroidism, osteomalac. And
rickets, osteopor., prim. and tert.
hyperparathyroidism, neonatal hypocalc.

Mineral Products. Potassium Phosphate (monobasic) 602 mg, Sodium Phosphate (dibasic) 285 mg.
TABS: 200. 3 tabs. on first day
foll. by 2 tabs. 3 x dly.
Prevent. and tmt. of calcium oxalate
stones.
C/I: Hypersens., sev. renal impair.,
hyperphosphatemia, urolithiasis.

Anti-Parathyroid Agent. Cinacalcet (as HCl) 30, 60, 90 mg.
F.C. TABS.: 28×30, 60, 90 mg. For hyperparathyroidism: init. dosage is 30 mg (one tab.) ×1/d.
For parathyroid cancer or prim. hyperparathyroidism: init. dosage is 30 mg (one tab.) ×2/d. Should be taken with food.
Tmt. of second. hyperparathyroidism (HPT) in pts. with end-stage ren. dis. (ESRD) on maint. dialysis ther.
May be used as part of a therap. regimen includ. phosphate binders and/or Vitamin D sterols, as appropr.
Reduct. of hypercalcaemia in pts. with parathyroid carcinom.
Reduct. of hypercalcaemia in pts. with:
Parathyroid carcinoma.
Prim. HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant tmt. guidelines), but in whom parathyroidectomy is not clinical. appropriate or is contraindic.
C/I: Hypersens.

Anti-Parathyroid Agent. Cinacalcet 30, 60, 90 mg.
F.C. TABS.: 14, 28, 30, 84. Usual start. is 30 mg, once per day. Parathyroid cancer/ prim. hyperparathyroidism: usual start. dose is 30mg×2/d with or shortly after food.
Tmt. of second. HPT in pts. with ESRD on maint. dialysis ther. As part of a therap. regimen includ. phosphate binders and/ or vitamin D sterols, as appropriate. Reduct. of hypercalcaemia in pts. with:
Parathyroid carcinoma, Primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinical. appropriate or is contraindicated.
C/I: Hypersens.

Topoisomerase II Inhibitor. Etoposide 20 mg/ml.
VIALS: 1x100 mg / 5 ml, 1x50 ml, 1x200
mg/10 ml. See lit.
Refract. testicular tumors, small cell lung
cancer, Hodgkin’s dis., malign. (non-
Hodgkin’s) lymphom. (espec. histocytic
type), acute non-lymph. leuk.
C/I: Hypersens. to compon.